691 Preston Building Nashville, TN 37232
Vanderbilt-Ingram Cancer Center provides compassionate care, evidence-based prevention, pioneering research, community engagement and survivorship support. Designated a Comprehensive Cancer Center by the National Cancer Institute and a member of the National Comprehensive Cancer Network, Vanderbilt-Ingram is at the forefront of discovery. Our teams of scientists and clinicians are defining personalized care with immunotherapies, targeted treatments, precision radiation-oncology, innovative surgeries, and novel imaging technologies.
Website: Vanderbilt-Ingram Cancer Center
A Phase 2 Study of CAbozantinib in Combination With AtezolizumaB as NeoAdjuvant Treatment for Muscle-Invasive BladdEr Cancer (ABATE)
Status: Open to Accrual
Read More
A Phase II Trial of Avelumab or Hydroxychloroquine with or without Palbociclib to Eliminate Dormant Breast Cancer (“PALAVY”)
Status: Open to Accrual
Read More
Innovative Combination Immunotherapy for Metastatic Triple Negative Breast Cancer (TNBC): A Multicenter, Multi-Arm Translational Breast Cancer Research Consortium Study
Status: Open to Accrual
Read More
Randomized phase 2 trial of gemcitabine + carboplatin + nivolumab versus gemcitabine + oxaliplatin + nivolumab in cisplatin-ineligible patients with metastatic urothelial cancer
Status: Closed to Accrual
Read More
A Randomized Phase II Study of Pembrolizumab, an Anti-PD (Programmed Cell Death)-1 Antibody, in Combination With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease
Status: Closed to Accrual
Read More
Facebook
Hoosier Cancer Research Network on Facebook
Linked In
You Tube
Twitter